v3.26.1
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Net revenue:    
Revenue from Contract with Customer $ 401,947 $ 458,505
Cost of revenue:    
Cost of Revenue [1] 290,493 311,538
Gross profit 111,454 146,967
Operating expenses:    
Research and development [2] 37,753 47,942
Selling and marketing 38,573 43,315
General and administrative 45,398 47,871
Restructuring 16,172 0
Total operating expenses 137,896 139,128
Income (loss) from operations (26,442) 7,839
Income from equity method investment 1,124 4,714
Interest expense (32,905) (12,954)
Gain on extinguishment of debt 0 1,475
IEEPA refund financing costs (2,405) 0
Gain (loss) from change in fair value of warrant liability 8,369 (499)
Other income, net 5,011 559
Income (loss) before provision for income taxes (47,248) 1,134
Provision for income taxes 1,946 2,725
Net loss $ (49,194) $ (1,591)
Net loss per share - basic and diluted (in dollars per share) $ (0.4) $ (0.02)
Weighted average common shares used in computing net loss per share:    
Basic and diluted (in shares) 122,635 102,768
Other Comprehensive Loss:    
Net loss $ (49,194) $ (1,591)
Unrealized gain from cash flow hedges, net of reclassifications 1,603 0
Foreign currency translation adjustment (3,237) 1,557
Change in defined benefit pension obligation (42) 828
Comprehensive income (loss) (50,870) 794
Product [Member]    
Net revenue:    
Revenue from Contract with Customer [3] 172,712 237,580
Cost of revenue:    
Cost of Revenue 132,297 162,569
Service [Member]    
Net revenue:    
Revenue from Contract with Customer [4] 229,235 220,925
Cost of revenue:    
Cost of Revenue $ 158,196 $ 148,969
[1] Includes cost of revenue from sales to the joint venture, an equity method investment, of $40,997 during the year ended June 30, 2026, and $74,421 during the year ended June 30, 2025. See Note 11.
[2] Includes charge backs to the joint venture, an equity method investment, related to research and development of $1,294 during the year ended June 30, 2026 and $1,482 during the year ended June 30, 2025.
[3] Includes sales of products to the joint venture, an equity method investment, of $42,965 during the year ended June 30, 2026, and $101,563 during the year ended June 30, 2025. See Note 11.
[4] Includes sales of services to the joint venture, an equity method investment, of $22,604 during the year ended June 30, 2026, and $18,521 during the year ended June 30, 2025. See Note 11.